These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 17296817

  • 1. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.
    Toschi L, Cappuzzo F.
    Oncologist; 2007 Feb; 12(2):211-20. PubMed ID: 17296817
    [Abstract] [Full Text] [Related]

  • 2. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA, Johnson BE.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [Abstract] [Full Text] [Related]

  • 3. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
    Bonomi PD, Buckingham L, Coon J.
    Clin Cancer Res; 2007 Aug 01; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dominance of EGFR and insignificant KRAS mutations in prediction of tyrosine-kinase therapy for NSCLC patients stratified by tumor subtype and smoking status.
    Pesek M, Benesova L, Belsanova B, Mukensnabl P, Bruha F, Minarik M.
    Anticancer Res; 2009 Jul 01; 29(7):2767-73. PubMed ID: 19596959
    [Abstract] [Full Text] [Related]

  • 8. Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.
    Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.
    Diagn Cytopathol; 2007 May 01; 35(5):257-62. PubMed ID: 17427221
    [Abstract] [Full Text] [Related]

  • 9. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK.
    Lung Cancer; 2008 Jun 01; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [Abstract] [Full Text] [Related]

  • 10. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T, Liu G, Tsao MS.
    Oncogene; 2009 Aug 01; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [Abstract] [Full Text] [Related]

  • 11. Should every lung cancer patient be tested for EGFR mutation?
    Cappuzzo F.
    Expert Opin Ther Targets; 2006 Dec 01; 10(6):789-91. PubMed ID: 17105366
    [Abstract] [Full Text] [Related]

  • 12. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
    Gow CH, Chien CR, Chang YL, Chiu YH, Kuo SH, Shih JY, Chang YC, Yu CJ, Yang CH, Yang PC.
    Clin Cancer Res; 2008 Jan 01; 14(1):162-8. PubMed ID: 18172267
    [Abstract] [Full Text] [Related]

  • 13. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
    Bianco R, Troiani T, Tortora G, Ciardiello F.
    Endocr Relat Cancer; 2005 Jul 01; 12 Suppl 1():S159-71. PubMed ID: 16113092
    [Abstract] [Full Text] [Related]

  • 14. Biology of interactions: antiepidermal growth factor receptor agents.
    Harari PM, Allen GW, Bonner JA.
    J Clin Oncol; 2007 Sep 10; 25(26):4057-65. PubMed ID: 17827454
    [Abstract] [Full Text] [Related]

  • 15. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A, Ribeiro R, Azevedo I, Coelho A, Soares M, Sousa B, Pinto D, Lopes C, Medeiros R, Scagliotti GV.
    Oncologist; 2007 Feb 10; 12(2):201-10. PubMed ID: 17296816
    [Abstract] [Full Text] [Related]

  • 16. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies.
    Patel JD.
    Curr Opin Oncol; 2006 Nov 10; 18(6):609-14. PubMed ID: 16988582
    [Abstract] [Full Text] [Related]

  • 17. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.
    Prudkin L, Wistuba II.
    Ann Diagn Pathol; 2006 Oct 10; 10(5):306-15. PubMed ID: 16979526
    [Abstract] [Full Text] [Related]

  • 18. EGFR mutations and the terminal respiratory unit.
    Yatabe Y.
    Cancer Metastasis Rev; 2010 Mar 10; 29(1):23-36. PubMed ID: 20135199
    [Abstract] [Full Text] [Related]

  • 19. [Studies for mechanism of drug resistance to EGFR-TKI].
    Yano S.
    Gan To Kagaku Ryoho; 2010 Aug 10; 37(8):1463-6. PubMed ID: 20860097
    [No Abstract] [Full Text] [Related]

  • 20. Targeting ADAMS and ERBBs in lung cancer.
    Hynes NE, Schlange T.
    Cancer Cell; 2006 Jul 10; 10(1):7-11. PubMed ID: 16843261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.